PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
26703450-3	2016	Pufferfish that received rIFN-gamma injection had an elevated phagocytic activity at 1 and 3 dpi, whereas rIFN-gammarel and rIL-4/13A treated fish showed an increased phagocytic activity only at 1 and 3 dpi, respectively.	13a	130-133	interleukin 4	Rattus norvegicus	124-129
27782099-4	2016	Further structure-based optimization revealed that 6-(2,6-dichloro-3,5-dimethoxyphenyl)-N-(3-(4-methylpiperazin-1-yl)phenyl)-1H-indazole-4-carboxamide (13a) is the most potent FGFR1 inhibitor in this series, with an enzyme inhibitory activity IC50 value of about 30.2 nM.	13a	152-155	fibroblast growth factor receptor 1	Homo sapiens	176-181
26703450-4	2016	Superoxide anion production increased only at 1 dpi in rIFN-gamma, rIFN-gammarel and rIL-4/13A injected pufferfish.	13a	91-94	interleukin 4	Rattus norvegicus	85-90
20536349-5	2010	Reporter assays demonstrated that compound 13a successfully relieved transcriptional repression by RAR-alpha, while 13b and 13c could not, demonstrating the critical role of the acid moiety in this binding.	13a	43-46	retinoic acid receptor alpha	Homo sapiens	99-108
23856049-3	2013	These efforts culminated in the discovery of compound 13a, a potent, relatively selective inhibitor of TAK1 with good pharmacokinetic properties in mice, which was active in an in vivo model of ovarian cancer.	13a	54-57	mitogen-activated protein kinase kinase kinase 7	Mus musculus	103-107
25419444-3	2014	We believe 13a represents a useful probe for interrogating STAT5 function in cells as well as being a potential candidate for advanced preclinical trials.	13a	11-14	signal transducer and activator of transcription 5A	Homo sapiens	59-64
19343204-10	2009	As proteins, either ME-13a- or ME-13b-containing isoform can cell-autonomously rescue the embryonic lethality caused by genetic loss of N-Cadherin.	13a	23-26	Cadherin-N	Drosophila melanogaster	136-146
20097709-12	2010	Insulin (5-10 nm) suppressed all TCF7L2 isoforms in SGBS cells but suppressed exon 13a-containing isoforms most significantly (P < 0.001).	13a	83-86	insulin	Homo sapiens	0-7
17409557-2	2007	Among the various fused furan derivatives synthesized, a benzothieno[3,2-b]furan derivative 13a displayed potent inhibitory activity towards IKKbeta in enzymatic and cellular assays.	13a	92-95	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	141-148
33272706-4	2021	Analogues with cyclohexylaminoethoxy (13a) or adamantylaminoethoxy BSC (13b) lacking a polar aromatic ring displayed high ER-binding affinity and ER antagonism in Ishikawa cells higher than raloxifene and similar to fulvestrant (ICI182,780).	13a	38-41	epiregulin	Homo sapiens	122-124
17173447-6	2006	The pKa* of the coordinated water in [(eta6-p-cym)Ru(azpyz-NMe2)OH2]2+ (13A) is 4.60, consistent with the increased acidity of the ruthenium center upon coordination to the azo ligand.	13a	72-75	NME/NM23 nucleoside diphosphate kinase 2	Homo sapiens	59-63
34378541-5	2021	In comparison with the well-known BRD4 inhibitor (+)-JQ1, 13a showed more potent anticancer activity in NF-kappaB-active MDA-MB-231 cells.	13a	58-61	nuclear factor kappa B subunit 1	Homo sapiens	104-113
9658576-9	1998	These data suggest that 13a may be an useful agent for the treatment of angiotensin II-dependent diseases, such as hypertension.	13a	24-27	angiotensinogen	Rattus norvegicus	72-86
34628225-5	2021	Molecular docking analysis suggested that 13a could interact with the catalytic active sites and the peripheral anion site of AChE, and bind to Abeta1-42 pentamers.	13a	42-45	acetylcholinesterase	Mus musculus	126-130
34628225-6	2021	Moreover, 13a effectively attenuated Abeta1-42 oligomers-induced cognitive dysfunction in mice by activating the cAMP-response element binding protein/brain-derived neurotrophic factor signaling pathway, decreasing tau phosphorylation, preventing synaptic toxicity, and inhibiting neuroinflammation.	13a	10-13	brain derived neurotrophic factor	Mus musculus	151-184
35489222-4	2022	Through structure-activity relationship studies, the most optimized compound 13a was developed as a potent inhibitor at FLT3 and FLT3/D835Y with IC50 values of 0.26 nM and 0.18 nM, respectively, which also displayed remarkably strong in vitro anticancer activities, with single-digit nanomolar GI50 values for several AML (MV4-11 and MOLM14) and Ba/F3 cell lines expressed with secondary TKD mutated FLT3 kinases as well as FLT3-ITD.	13a	77-80	fms related receptor tyrosine kinase 3	Homo sapiens	120-124
35489222-4	2022	Through structure-activity relationship studies, the most optimized compound 13a was developed as a potent inhibitor at FLT3 and FLT3/D835Y with IC50 values of 0.26 nM and 0.18 nM, respectively, which also displayed remarkably strong in vitro anticancer activities, with single-digit nanomolar GI50 values for several AML (MV4-11 and MOLM14) and Ba/F3 cell lines expressed with secondary TKD mutated FLT3 kinases as well as FLT3-ITD.	13a	77-80	fms related receptor tyrosine kinase 3	Homo sapiens	129-133
35489222-4	2022	Through structure-activity relationship studies, the most optimized compound 13a was developed as a potent inhibitor at FLT3 and FLT3/D835Y with IC50 values of 0.26 nM and 0.18 nM, respectively, which also displayed remarkably strong in vitro anticancer activities, with single-digit nanomolar GI50 values for several AML (MV4-11 and MOLM14) and Ba/F3 cell lines expressed with secondary TKD mutated FLT3 kinases as well as FLT3-ITD.	13a	77-80	FMS-like tyrosine kinase 3	Mus musculus	400-404
35489222-4	2022	Through structure-activity relationship studies, the most optimized compound 13a was developed as a potent inhibitor at FLT3 and FLT3/D835Y with IC50 values of 0.26 nM and 0.18 nM, respectively, which also displayed remarkably strong in vitro anticancer activities, with single-digit nanomolar GI50 values for several AML (MV4-11 and MOLM14) and Ba/F3 cell lines expressed with secondary TKD mutated FLT3 kinases as well as FLT3-ITD.	13a	77-80	FMS-like tyrosine kinase 3	Mus musculus	424-428
35489222-6	2022	Furthermore, significant in vivo anticancer efficacy of compound 13a was confirmed in a xenograft animal model implanted with FLT3-ITD/D835Y-expressing MOLM-14 cells related to secondary TKD mutation.	13a	65-68	fms related receptor tyrosine kinase 3	Homo sapiens	126-130
33272706-4	2021	Analogues with cyclohexylaminoethoxy (13a) or adamantylaminoethoxy BSC (13b) lacking a polar aromatic ring displayed high ER-binding affinity and ER antagonism in Ishikawa cells higher than raloxifene and similar to fulvestrant (ICI182,780).	13a	38-41	epiregulin	Homo sapiens	146-148
32631508-4	2020	Further exploration of possible mechanism of action indicates that 13a not only activates ROS production through NQO1-directed redox cycling but also inhibits the phosphorylation of STAT3.	13a	67-70	NAD(P)H quinone dehydrogenase 1	Homo sapiens	113-117
32886510-7	2020	Liquid chromatography-mass spectrometry (LC-MS) analysis confirmed that 13a modified selenocysteine 498 (U) residues in the redox centers of TrxR, resulting in enzyme inhibition.	13a	72-75	peroxiredoxin 5	Homo sapiens	141-145
32886510-8	2020	Therefore, compound 13a acts as a novel TrxR inhibitor and may be a promising candidate for cancer intervention.	13a	20-23	peroxiredoxin 5	Homo sapiens	40-44
32912435-7	2020	All the results showed that 13a was a promising EGFR inhibitor.	13a	28-31	epidermal growth factor receptor	Homo sapiens	48-52
32631508-5	2020	These findings indicate that 13a has potential use for the development of new skeleton drug candidate as an efficient substrate of NQO1 and STAT3 inhibitor.	13a	29-32	NAD(P)H quinone dehydrogenase 1	Homo sapiens	131-135
32631508-4	2020	Further exploration of possible mechanism of action indicates that 13a not only activates ROS production through NQO1-directed redox cycling but also inhibits the phosphorylation of STAT3.	13a	67-70	signal transducer and activator of transcription 3	Homo sapiens	182-187
32631508-5	2020	These findings indicate that 13a has potential use for the development of new skeleton drug candidate as an efficient substrate of NQO1 and STAT3 inhibitor.	13a	29-32	signal transducer and activator of transcription 3	Homo sapiens	140-145
30360747-18	2019	Among these compounds the derivative 13a showed best IC50 value of 63.34 microg mL-1 (182.86 microM).	13a	37-40	L1 cell adhesion molecule	Mus musculus	80-84
32321249-3	2020	Lead inhibitor 13a shows picomolar or low nanomolar IC50 against HDAC1 and HDAC3 and exhibits differential toxicity profiles toward multiple cancer cells with different FLT3 and p53 status.	13a	15-18	histone deacetylase 1	Homo sapiens	65-70
32321249-3	2020	Lead inhibitor 13a shows picomolar or low nanomolar IC50 against HDAC1 and HDAC3 and exhibits differential toxicity profiles toward multiple cancer cells with different FLT3 and p53 status.	13a	15-18	histone deacetylase 3	Homo sapiens	75-80
30885648-7	2019	Furthermore, the docking results of 13a revealed that the oxygen atom at the position of C-3 connected to the heme of CYP17, which may be helpful for its satisfactory dual-target inhibition.	13a	36-39	cytochrome P450 family 17 subfamily A member 1	Homo sapiens	118-123
32321249-3	2020	Lead inhibitor 13a shows picomolar or low nanomolar IC50 against HDAC1 and HDAC3 and exhibits differential toxicity profiles toward multiple cancer cells with different FLT3 and p53 status.	13a	15-18	fms related receptor tyrosine kinase 3	Homo sapiens	169-173
32321249-3	2020	Lead inhibitor 13a shows picomolar or low nanomolar IC50 against HDAC1 and HDAC3 and exhibits differential toxicity profiles toward multiple cancer cells with different FLT3 and p53 status.	13a	15-18	tumor protein p53	Homo sapiens	178-181
32321249-4	2020	13a indirectly inhibits the FLT3 signaling pathway and down-regulates the master anti-apoptotic proteins, resulting in the activation of pro-caspase3 in in wt-p53 FLT3-ITD MV4-11 cells.	13a	0-3	fms related receptor tyrosine kinase 3	Homo sapiens	28-32
32321249-4	2020	13a indirectly inhibits the FLT3 signaling pathway and down-regulates the master anti-apoptotic proteins, resulting in the activation of pro-caspase3 in in wt-p53 FLT3-ITD MV4-11 cells.	13a	0-3	caspase 3	Homo sapiens	141-149
32321249-4	2020	13a indirectly inhibits the FLT3 signaling pathway and down-regulates the master anti-apoptotic proteins, resulting in the activation of pro-caspase3 in in wt-p53 FLT3-ITD MV4-11 cells.	13a	0-3	tumor protein p53	Homo sapiens	159-162
32321249-4	2020	13a indirectly inhibits the FLT3 signaling pathway and down-regulates the master anti-apoptotic proteins, resulting in the activation of pro-caspase3 in in wt-p53 FLT3-ITD MV4-11 cells.	13a	0-3	fms related receptor tyrosine kinase 3	Homo sapiens	163-167
32321249-6	2020	The MDM2 antagonist and the proteasome inhibitor promote 13a-triggered apoptosis by preventing p53 degradation.	13a	57-60	MDM2 proto-oncogene	Homo sapiens	4-8
32321249-6	2020	The MDM2 antagonist and the proteasome inhibitor promote 13a-triggered apoptosis by preventing p53 degradation.	13a	57-60	tumor protein p53	Homo sapiens	95-98
29983575-0	2018	CAT3, a prodrug of 13a(S)-3-hydroxyl-6,7-dimethoxyphenanthro[9,10-b]-indolizidine, circumvents temozolomide-resistant glioblastoma via the Hedgehog signaling pathway, independently of O6-methylguanine DNA methyltransferase expression.	13a	19-22	solute carrier family 7 member 3	Homo sapiens	0-4
29983575-0	2018	CAT3, a prodrug of 13a(S)-3-hydroxyl-6,7-dimethoxyphenanthro[9,10-b]-indolizidine, circumvents temozolomide-resistant glioblastoma via the Hedgehog signaling pathway, independently of O6-methylguanine DNA methyltransferase expression.	13a	19-22	O-6-methylguanine-DNA methyltransferase	Homo sapiens	184-222
29235893-4	2018	RESULTS & DISCUSSION: The furoaurone derivative, 13a was the most active one exhibiting promising growth inhibition against leukemia, K562 and melanoma, MDA-MB-435 cells at concentration of 10 muM.	13a	53-56	latexin	Homo sapiens	197-200
29235893-7	2018	Simulation docking study was undertaken to gain insight into the possible binding mode of 13a in the CDK2 enzyme.	13a	90-93	cyclin dependent kinase 2	Homo sapiens	101-105
29944015-6	2018	Also, 13a displayed significant increase in the percentage of annexin V-FITC positive apoptotic cells from 1.75-13.76%.	13a	6-9	annexin A5	Homo sapiens	62-71